-
HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
Announcing a new article publication for BIO Integration journal. Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (∼150 kDa), which markedly slows diffusion through the interstitium of solid tumors and prevents efficient…
-
Integration of Reactive Oxygen Species Generation and Prodrug Activation for Cancer Therapy
Announcing a new article publication for BIO Integration journal. In this article the authors Xiao’en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang from Tianjin University, Tianjin, China discuss the integration of reactive oxygen species generation and prodrug activation for cancer therapy. The combination of chemotherapeutic drugs and…
-
Theranostics in Cancer Therapy: Integration for Transformative Research
In this short video extract Professor Phei Er Saw, Executive Editor, BIOI, introduces a presentation from Dr Xiaoyuan (Shawn) Chen, National Institutes of Health, Bethesda, MD, USA, on Theranostics in Cancer Therapy: Integration for Transformative Research. Dr Chen discusses cancer radiotheranostics, cancer immunotheranostics and ROS theranostics: A full video of…
-
Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy– BIO Integration
Announcing a new article publication for BIO Integration journal. In this mini review article the authors Yuhao Chen, Meng Du, Jinsui Yu, Lang Rao, Xiaoyuan Chen and Zhiyi Chen from The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China and the National Institute of Biomedical Imaging and Bioengineering, Bethesda,…
